STAG2 mutation predicts superior posttransplant survival in acute myeloid leukemia treated with low-intensity induction

• by Yu-Sung Chang, Hsin-An Hou

• October 31, 2026

Engineering a New Generation of Cancer-Fighting Cells

USC researchers develop a scalable cell engineering platform that could overcome key manufacturing and therapeutic limitations of CAR-based immunotherapies

• October 28, 2026

• 3 min

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

• by Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Wangjun Liao, Xiaohui He, Xiaozhong Chen, Zhigang Liu, Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching-Yun Hsieh, Muh-Hwa Yang, Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu

• October 27, 2026

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

• by Adam D. Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P. Laubach, Sheeba K. Thomas, Simon J. Harrison, Luciano J. Costa, Andrew Spencer, Rafael Fonseca, Peter A. Forsberg, Jesus G. Berdeja, Rayan Kaedbey, Nizar J. Bahlis, Paula Rodriguez-Otero, Maria-Victoria Mateos, Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong, James Cooper, Amrita Krishnan

• October 20, 2026